Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCX-1777 (Forodesine) in Refractory CTCL
NCT00061880Phase 2Completed
- Sponsor
- BioCryst Pharmaceuticals, Inc.
- Start
- Feb 2003
- Primary completion
- Jan 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of forodesine in cutaneous T-cell lymphoma (CTCL), sponsored by BioCryst Pharmaceuticals, Inc.. Started Feb 2003; status: completed.
02
Drugs
forodesine
03
Conditions
cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT00061880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00061880.